Quantitative mass spectrometric immunoassay of insulin like growth factor 1

Journal of Proteome Research

Volumn 3, Issue 4, 2004, Pages 851-855

  Nelson, Randall W ^a   Nedelkov, Dobrin ^a   Tubbs, Kemmons A ^a   Kiernan, Urban A ^a  

^a Intrinsic Bioprobes Incorporated   (United States)

Author keywords

IGF; Immunoassay; Mass spectrometry; Quantification

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN C;

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; COMPLEX FORMATION; DEVICE; EXTRACTION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOASSAY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; RAT; ROBOTICS; STANDARD;

ANIMALS; HUMANS; IMMUNOASSAY; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MASS SPECTROMETRY; RATS;

EID: 4444381540     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr0499388     Document Type: Article

References (26)

1. Zapf, J.; Froesch, E. R.; Schmid, C. Metabolic Effects of IGFs. In. Contemporary Endocrinology 17: The IGF System - Molecular Biology, Physiology and Clinical Applications; Conn, M., Ed.; Humana Press: New Jersey, 1999.
2. Strasburger, C. J.; Bidlingmaier, M.; Wu, Z.; Morrison, K. M. Normal values of insulin-like growth factor I and their clinical utility in adults. Horm. Res. 2001, 55 Suppl. 2, 100-105.
3. Brabant, G.; von zur Muhlen, A.; Wuster, C., et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm. Res. 2003, 60, 53-60.
4. Monzavi, R.; Cohen, P. IGFs and IGFBPs: role in health and disease. Best Pract. Res. Clin. Endocrinol. Metab. 2002, 16, 433-447.
5. Wolk, A.; Mantzoros, C. S.; Andersson, S. O., et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. 1998, 90, 911-915.
6. Chan, J. M.; Stampfer, M. J.; Giovannucci, E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279, 563-566.
7. Hankinson, S. E.; Willett, W. C.; Colditz, G. A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998, 351, 1393-1396.
8. Chestnut, R. E.; Quarmby, V. Evaluation of total IGF-I assay methods using samples from Type I and Type II diabetic patients. J. Immunol. Methods 2002, 259, 11-24.
9. Clemmons, D. R. Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Horm. Res. 2001, 55, 73-79.
10. Bobin, S.; Popot, M. A.; Bonnaire, Y.; Tabet, J. C. Approach to the determination of insulin-like-growth-factor-I (IGF-I) concentration in plasma by high-performance liquid chromatographyion trap mass spectrometry: use of a deconvolution algorithm for the quantification of multiprotonated molecules in electrospray ionization. Analyst 2001, 126, 1996-2001.
11. de Kock, S. S.; Rodgers, J. P.; Swanepoel, B. C. Growth hormone abuse in the horse: preliminary assessment of a mass spectrometric procedure for IGF-1 identification and quantitation. Rapid Commun Mass Spectrom 2001, 15, 1191-1197.
12. Nelson, R. W.; Krone, J. R.; Bieber, A. L.; Williams, P. Mass-Spectrometric Immunoassay. Anal. Chem. 1995, 67, 1153-1158.
13. Tubbs, K. A.; Nedelkov, D.; Nelson, R. W. Detection and quantification of beta-2-microglobulin using mass spectrometric immunoassay. Anal. Biochem. 2001, 289, 26-35.
14. Niederkofler, E. E.; Tubbs, K. A.; Gruber, K. et al. Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. Anal. Chem. 2001, 73, 3294-3299.
15. Kiernan, U. A.; Tubbs, K. A.; Gruber, K., et al. High-Throughput Protein Characterization Using Mass Spectrometric Immunoassay. Anal. Biochem. 2002, 301, 49-56.
16. Kiernan, U. A.; Nedelkov, D.; Tubbs, K. A.; Niederkofler, E. E.; Nelson, R. W. High-throughput analysis of human plasma proteins. Am. Biotech. Lab 2002, 20, 26-28.
17. Kiernan, U. A.; Tubbs, K. A.; Nedelkov, D.; Niederkofler, E. E.; Nelson, R. W. Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. Biochem. Biophys. Res. Commun. 2002, 297, 401-405.
18. Niederkofler, E. E.; Tubbs, K. A.; Kiernan, U. A.; Nedelkov, D.; Nelson, R. W. Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J. Lipid Res. 2003, 44, 630-639.
19. Kiernan, U. A.; Tubbs, K. A.; Nedelkov, D.; Niederkofler, E. E.; Nelson, R. W. Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett. 2003, 537, 166-170.
20. Kiernan, U. A.; Tubbs, K. A.; Nedelkov, D.; Niederkofler, E. E.; McConnell, E.; Nelson, R. W. Comparative urine protein phenotyping using mass spectrometric immunoassay. J. Proteome Res. 2003, 2, 191-197.
21. Baxter, R. C. Insulin-like growth factor binding proteins in the human circulation: a review. Horm. Res. 1994, 42, 140-144.
22. Blum, W. F.; Breier, B. H. 1994 Radioimmunoassays for IGFs and IGFBPs. Growth Regul. 4 Suppl 1: 11-119.
23. Bang, P.; Baxter, R. C.; Blum, W. F., et al. Valid measurements of total IGF concentrations in biological fluids. Recommendations from the 3rd International Symposium on Insulin-like Growth Factors. J. Endocrinol. 1994, 143, C1-2.
24. Nedelkov, D.; Nelson, R. W.; Kiernan, U. A.; Niederkofler, E. E.; Tubbs, K. A. Detection of bound and free IGF-1 and IGF-2 in human plasma via biomolecular interaction analysis mass spectrometry. FEBS Lett. 2003, 536, 130-134.
25. Nelson, R. W.; McLean, M. A.; Hutchens, T. W. Quantitative-Determination of Proteins By Matrix-Assisted Laser-Desorption Ionization Time-of-Flight Mass-Spectrometry. Anal. Chem. 1994, 66, 1408-1415.
26. Renehan, A. G.; Jones, J.; O'Dwyer, S. T.; Shalet, S. M. Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. Growth Horm. IGF Res. 2003, 13, 341-346.